Search

Edwards Lifesciences Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

92.26 1.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

90.19

Max

91.64

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-139M

241M

Pardavimai

92M

1.7B

P/E

Sektoriaus vid.

54.054

57.371

Pelnas, tenkantis vienai akcijai

0.78

Pelno marža

13.866

Darbuotojai

16,000

EBITDA

20M

520M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+13.29% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3.3B

52B

Ankstesnė atidarymo kaina

90.84

Ankstesnė uždarymo kaina

92.26

Naujienos nuotaikos

By Acuity

33%

67%

112 / 340 reitingas Healthcare

Edwards Lifesciences Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-18 23:06; UTC

Edwards Lifesciences shares are lower in after-market hours amid rising U.S. bond yields, contributing to market concerns despite recent softer economic data.

2026-08-13 20:06; UTC

Edwards Lifesciences shares are lower today, tracking a broader market decline. The stock remains above its 20-day moving average and near its one-month range.

2026-08-12 22:16; UTC

Edwards Lifesciences shares declined in after-market trading, despite earlier fluctuations. The stock remains above its 20-day moving average and near its one-month range.

2026-08-11 19:21; UTC

Edwards Lifesciences Corp is trading higher, maintaining upward momentum after four consecutive daily gains and peaking in the late morning session.

2026-08-10 19:51; UTC

Edwards Lifesciences shares are higher today, reflecting unusual strength above the 20-day moving average amid uncertainty over the Federal Reserve's interest rate policy.

2026-08-07 19:16; UTC

Edwards Lifesciences Corp. shares are higher today, fluctuating within a routine range since Thursday's close, currently trading above its 20-day moving average.

2026-08-05 19:56; UTC

Edwards Lifesciences shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average.

2026-08-04 19:36; UTC

Edwards Lifesciences shares are higher amid positive market momentum, despite a notable decline in U.S. core factory orders reflecting weakening demand across sectors.

2026-08-03 22:02; UTC

Edwards Lifesciences Corp shares are lower in after-market hours, following a notable decline that reached a session low shortly after the market opened.

2026-07-31 19:46; UTC

Edwards Lifesciences shares are lower, reflecting broader market trends amid inflation and interest rate concerns. The stock is trading below its 20-day moving average.

2026-07-30 22:06; UTC

Edwards Lifesciences shares are trading lower in after-market hours, reflecting ongoing weakness and uncertainty following the Federal Reserve's interest rate decision.

2026-07-29 23:46; UTC

Edwards Lifesciences Corp shares are higher in after-market trading, following four consecutive sessions of gains. No specific news was identified to explain the movement.

2026-07-28 18:46; UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

2026-07-27 19:41; UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

2026-07-24 18:41; UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

2026-07-23 23:41; UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

2026-07-22 18:46; UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

2026-07-21 21:02; UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

2026-07-20 19:56; UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Akcijų palyginimas

Kainos pokytis

Edwards Lifesciences Corp Prognozė

Kainos tikslas

By TipRanks

13.29% į viršų

12 mėnesių prognozė

Vidutinis 102.88 USD  13.29%

Aukščiausias 110 USD

Žemiausias 85 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Edwards Lifesciences Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

16

Pirkti

3

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

112 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat